ArticleCureus2026
When Prostate Cancer Mimics Multiple Myeloma: Diffuse Bone Marrow Infiltration Revealing Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse bone marrow infiltration is an uncommon manifestation of metastatic prostate adenocarcinoma and may mimic hematologic malignancies such as multiple myeloma, resulting in diagnostic delay. Neuroendocrine differentiation further complicates the clinical presentation because of its aggressive biological behavior and atypical metastatic pattern. We report a rare case of metastatic prostate adenocarcinoma with neuroendocrine differentiation revealed by diffuse bone marrow infiltration. A 59-year-old man presented with diffuse bone pain and pancytopenia and was initially admitted to the hematology department because of suspected multiple myeloma. Bone marrow examination revealed infiltration by malignant epithelial cells, prompting referral for oncological evaluation. Further investigations demonstrated high-grade metastatic prostate adenocarcinoma with neuroendocrine differentiation associated with extensive osteomedullary involvement. The patient received an intensified therapeutic strategy combining androgen deprivation therapy, abiraterone acetate, and platinum-based chemotherapy with docetaxel and carboplatin. This case highlights the importance of considering metastatic prostate cancer in the differential diagnosis of unexplained cytopenia and diffuse bone lesions in male patients. It also emphasizes the diagnostic value of bone marrow examination and the need to recognize aggressive neuroendocrine variants requiring adapted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.